Editorial
Welcome to the March edition of i2P – Information to Pharmacists.
You may have noiticed if you receive i2P by email, that we have simplified our mail out presentation.
This was because the code in our earlier version appeared to be too unstable to maintain, hence the simpler presentation.
Columns
Rollo Manning: Pharma-Goss
John Dunlop: Inside NZ
Loretta Marron BSc: Health Watch
Barry Urquhart: Marketing Focus
Harvey Mackay: Strategic Thinking
Mark Neuenschwander: I`ve been thinking about...Recent Comments
Past Editions
Volume 1 Number 1
Volume 1 Number 2
Volume 1 Number 3
Volume 1 Number 4
Volume 1 Number 5
Volume 1 Number 6
Volume 1 Number 7
Volume 2 Number 1
Volume 2 Number 2
Pharma News
Staff Writer: SIGMA Pharmaceuticals suspends share trading before release of revised earnings outlookHospital News
Health Politics
Pat Gallagher: Health Informatics - The State of the Nation
Peter Sayers: The Three-Ring Circus
Dr David More: e-Health IdentifiersEPublications
This Month in Pharmacy – July 2009
Printer-friendly version
Send to friend
PDF version | From the desk of the editor |
Introducing current ideas, perspectives and issues, to the profession of pharmacy | |
Welcome to the July edition of i2P, and of course, the first week of the new financial year. Note that we are developing a new range of categories for you to follow e.g. health politics, hospital news, an expanded IT offer and we will be developing the category of anti-ageing medicine Also, out of interest, could I refer you to the e-publications category located immediately below our columnists. If you click on the link contained there, you will find a range of e-publications that are recommended reading. The first publication noted is the Pharmacist Activist written by Dr Daniel A. Hussar of the faculty of the Philadelphia College of Pharmacy at the University of the Sciences in Philadelphia. He is a pharmacy advocate.
In his latest edition he is advocating for a change for the way in which prescription benefits are managed and the treatment that pharmacy receives in the US.
When you make the comparison with the situation here in Australia you can well believe that the Australian equivalent, while definitely not perfect, is well ahead of its US counterpart.
The other interesting news is that New Zealand is about to fund a range of unspecified clinical programs and separating the cost out of prescription prices.
This is good news and bad news because it will be a cause for major adjustment for individual pharmacists.
We have five of our opinion writers in this edition (located in the tripartite column in the centre of the page). Don’t forget to click on the other links (Recent News and Pharmedia).
Our Pharmedia commentary concerns the Terry White group and the strong moves they are flagging to our industry. This is a group worth following.
There is good and bad news in the IT segment of i2P this month.
Pat Gallagher and David More highlight some of the “bad” elements while we found some “good” elements in a press release from the HealthConnect SA program.
All worth reading before you rush out and invest in software that may not see the distance.
Aged Care is a new category for i2P, but given the number of Dose Administration Aids handled by pharmacists, it is worth following any newsworthy events.
Last month we reported that investment in aged care facilities had fallen significantly, hastening the inevitable move to service patients in their home.
If you don’t have a “pharmacy in the home” project of your own, now is the time to get really involved.
Expensive at first to establish the infrastructure and trained staff, but represents an opportunity to establish a presence uncluttered by supermarkets and at a highly personal level.
I would also point you to the article by James Ellerson concerning independent pharmacist practitioners. If you are one of the 65% silent majority and you feel unrepresented and disoriented I suggest you follow this writer.
Also new to this edition is the comment panel at the foot of each article.
Please feel free to join in the discussion around any article.
Your comments may remain anonymous simply by request, but we must have your valid details before we can publish any comment.
Enjoy this month’s i2P and we will be bringing you new features each month for your consideration
Neil Johnston
July 2009
Return to home
Dr Andrew Byrne & Associates: Fatal torsade tachycardia due to methadone either rare or non-existent finds Norwegian study
Neil Retallick: A time of pivotal change will require new ways of thinking about community pharmacy
Neil Johnston: Dispensing errors and criminality
Post new comment